


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 38/16, 38/39, 48/00, 49/00, C12N 15/00, 15/10, 15/48, 15/86		A1	(11) International Publication Number: WO 95/26200
			(43) International Publication Date: 5 October 1995 (05.10.95)
(21) International Application Number: PCT/US95/03817		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 27 March 1995 (27.03.95)		Published With international search report.	
(30) Priority Data: 08/218,355 25 March 1994 (25.03.94) US			
(60) Parent Application or Grant (63) Related by Continuation US 08/218,355 (CIP) Filed on 25 March 1994 (25.03.94)			
(71) Applicant (for all designated States except US): INDIANA UNIVERSITY FOUNDATION [US/US]; P.O. Box 500, Showalter House, Bloomington, IN 47404 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): WILLIAMS, David, A. [US/US]; 8751 N. Moore Road, Indianapolis, IN 46278 (US). PATEL, Vikram, P. [US/US]; 18433 Wachs Terrace, Olney, MD 20832 (US).			
(74) Agent: GANDY, Kenneth, A.; Woodard, Emhardt, Naughton, Moriarty & McNett, Bank One Center/Tower, Suite 3700, 111 Monument Circle, Indianapolis, IN 46204 (US).			
(54) Title: ENHANCED VIRUS-MEDIATED DNA TRANSFER			



(57) Abstract

A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. As can be seen in the figure, the fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ENHANCED VIRUS-MEDIATED DNA TRANSFER

5

FIELD OF THE INVENTION

The present invention relates generally to methods for
10 increasing the efficiency of transduction of cells by viruses, and
more particularly to methods for enhancing viral-mediated gene
transfer into cells utilizing fibronectin and/or fibronectin fragments.

BACKGROUND OF THE INVENTION

15

Progress in understanding the molecular basis of many human
diseases as well as improvement in gene transfer technology has led
to recent attempts to develop protocols for somatic gene therapy for
severe genetic diseases. Currently, promising disease candidates for
20 human gene therapy include those in which an enzyme or other
protein is defective or missing, where the level of enzyme or protein

-2-

does not need to be exactly regulated, especially those that are constitutively regulated, and those defects which are found in the patient's bone marrow.

5 For example, one disease candidate for gene therapy is adenosine deaminase (ADA) deficiency which results in severe combined immunodeficiency disease (SCID). ADA deficient patients have little or no detectable enzyme in bone marrow cells. However, ADA deficiency has been cured by matched bone marrow
10 transplantation. ADA normal cells have a selective advantage over ADA deficient cells and will normally repopulate the patient's bone marrow.

Bone marrow cells are a good target for somatic gene therapy
15 because bone marrow tissue is easily manipulated *in vitro* and contains repopulating cells. Alternatively, human cord blood has previously also been demonstrated to contain a large number of primitive progenitor cells. Successful gene transfer into hematopoietic stem cells, the long term repopulating cells, may lead
20 to lifelong cures for a variety of diseases manifested in the progeny of these cells.

Gene transfer into, and long term gene expression in, repopulating stem cells has been achieved in murine models by a
25 number of investigators. However, *in vivo* experiments in larger animals, such as dogs and primates, have met with limited success,

-3-

largely due to the low efficiency of infection of primitive hematopoietic stem cells. The limitations of current gene transfer technology are further complicated when applied to human protocols by several factors, including the low numbers of stem cells present in adult bone marrow (ABM), the lack of suitable methods to
5 purify these cells, and the low fraction of such primitive cells in cell cycle.

In both murine and large animal experiments involving bone
10 marrow cells, it has been noted that the most successful protocols utilize cocultivation of target cells with retroviral producer cell lines. Also, most of the FDA- approved gene transfer trials in humans rely on recombinant retroviral vectors for gene transduction. Recombinant retroviral vectors are desirable for gene therapy
15 because they efficiently transfer and precisely and stably integrate exogenous DNA into cellular DNA. These vectors contain exogenous DNA for gene transfer and are further modified to eliminate viral pathogenicity. Because of these modifications, viral production is generally accomplished using retrovirus packaging cells. However,
20 for clinical gene therapy, cell-free transduction is more desirable due to concerns about bio-safety and quality control. Unfortunately, efficient gene transfer into hematopoietic cells such as stem cells has generally not been possible without cocultivation with virus-producing cells.

-4-

Recently, it has been shown that gene transfer efficiency can be increased by exposing target cells to stromal cells during infection. Stromal cells are a major component of the hematopoietic microenvironment (HM). The HM consists of an organized network of macrophages, stromal cells, endothelial cells, adipocytes and a complex extracellular matrix (ECM) made up of a variety of defined adhesion molecules. ECM molecules such as laminin, collagen, thrombospondin, proteoglycans, glycosaminoglycans and fibronectin provide anchorage sites for both hematopoietic cells and growth factors. The mechanism underlying this promoting effect of stroma on retroviral infection is unclear, but it has been known for some time that physiologic regulation of the proliferation and differentiation of hematopoietic cells occurs when these cells are in direct contact with cells of the HM.

15

Efficient gene transfer into long term repopulating hematopoietic stem cells and other cells remains problematic, inhibiting the widespread application of gene transfer protocols for curative therapy of hematopoietic and other diseases at present. A need persists for methods for efficient transfer of genetic material into mammalian cells without the dangers and limitations of past methods. The present invention addresses these needs.

20

SUMMARY OF THE INVENTION

Briefly, one preferred embodiment of this invention provides a method for increasing the frequency of transduction of hematopoietic cells by a retrovirus vector. The method includes infecting viable hematopoietic cells with a replication-defective recombinant retrovirus vector in the presence of substantially pure fibronectin and/or fibronectin fragments effective to increase the frequency of cellular transduction by the retrovirus. The fibronectin and/or fibronectin fragments can be derived from naturally-occurring materials or can be synthetically derived (e.g. genetically engineered by recombinant or chemical synthesis techniques), or derived from a combination of naturally-occurring and synthetic materials. In addition, it will be understood that the fibronectin polypeptide or polypeptides utilized in the invention may include mutations to the naturally-occurring fibronectin amino acid sequence which nonetheless provide functional polypeptides having the adhesion properties necessary for achieving enhanced transduction in accordance with the invention.

20

Another preferred embodiment of the invention provides a method for producing transduced hematopoietic cells which includes infecting viable hematopoietic cells with a replication-defective recombinant retrovirus carrying exogenous DNA in the presence of immobilized fibronectin, immobilized fibronectin fragments, or an

25

-6-

immobilized mixture thereof in amounts effective to increase the frequency of cellular transduction by the retrovirus.

Another preferred embodiment of the invention provides an improved method for cellular grafting. The method includes the steps of obtaining viable hematopoietic cells from an animal donor; infecting the hematopoietic cells with a recombinant retrovirus vector to produce transduced viable hematopoietic cells, the infecting being in the presence of fibronectin and/or a fragment thereof in immobilized form and effective to increase the frequency of transduction; and introducing the transduced viable hematopoietic cells into an animal recipient as a cellular graft. In one preferred mode the infected cells can be introduced into an autologous donor.

15

Another preferred embodiment of the present invention provides a method for obtaining transduced umbilical cord blood cells suitable for a cellular engraftment procedure. The method includes infecting hematopoietic cells from umbilical cord blood with a replication-defective recombinant retrovirus vector in the presence of an effective immobilized amount of fibronectin and/or fibronectin fragments to increase the frequency of transduction of the hematopoietic cells by the retrovirus vector. The invention also includes viable transduced cellular populations from umbilical cord blood obtainable by such a method, and cellular grafting methods

25

-7-

which include introducing the transduced cellular populations into an animal as a cellular graft.

In accordance with more specific aspects of the above-mentioned embodiments of the invention, the fibronectin or fibronectin fragment utilized will contain a first amino acid sequence which provides the retroviral-binding activity of the Heparin-II-binding domain of fibronectin, and a second amino acid sequence which provides the cell-binding activity of the CS-1 domain of fibronectin. The use of these two binding domains of fibronectin together has proven to very significantly enhance the transduction efficiency of the target cells by the retrovirus.

Another preferred embodiment of the invention provides a method for producing a construct for enhancing the frequency of transduction of a predetermined target cell by a retrovirus vector. The method includes the step of covalently coupling a ligand which binds to said target cell to a polypeptide containing an amino acid sequence which provides the retroviral-binding activity of the Heparin-II binding domain of fibronectin. The present invention also includes methods involving the utilization of these constructs to increase the frequency of transduction of the predetermined target cells by a retrovirus vector, and to engraftment procedures utilizing the transduced cells.

-8-

Another preferred embodiment of the invention provides a method for localizing an amount of a virus, comprising incubating a medium containing the virus in the presence of an effective immobilized amount of fibronectin or fragments of fibronectin
5 containing the viral-binding activity of the Heparin-II binding domain of fibronectin to localize an amount of the virus.

Still other preferred embodiments of the invention generally provide transduced viable hematopoietic and other cellular cultures
10 containing substantially pure and/or immobilized fibronectin or fragments thereof, as well as kits for conducting retroviral-mediated DNA transfer into cells, as further described in the passages which follow.

15 It is an object of this invention to provide methods for efficient retroviral infection of mammalian cells.

It is a further object of this invention to provide methods for gene transfer with retroviral vectors which avoid the need for
20 cocultivation.

It is a further object of the invention to provide improved methods and cellular cultures for autologous and/or allogeneic cellular grafting.

-9-

These and other objects, advantages, and features of the invention will be readily apparent to the skilled artisan from the following description.

DESCRIPTION OF THE FIGURES

FIG. 1 provides a schematic representation of a fibronectin
5 molecule, including chymotryptic fragments.

FIG. 2 shows the infection efficiency of committed human
progenitor cells in the presence of fibronectin fragments using the
TKNEO vector, as further described in Example 1, *infra*.

10

FIG. 3 compares the infection efficiency of various committed
human hematopoietic progenitor cells in the presence of fibronectin
fragments thereof using the TKNEO vector, as further described in
Example 1, *infra*.

15

FIG. 4 compares the presence of hADA in mice engrafted with
bone marrow cells transduced by (i) the coculture method (lanes 2-
4), (ii) supernatant infection in the presence of immobilized
fibronectin fragments (lanes 5-7), and supernatant infection on BSA
20 (lanes 8-10), as further described in Example 7, *infra*. Controls for
hADA are shown in lanes 1 and 12 and for murine ADA in lane 11.

FIG. 5 demonstrates retroviral binding to fibronectin fragments,
as further described in Example 8, *infra*.

25

-11-

FIG. 6 demonstrates that retroviral binding to fibronectin fragments is dose-dependent, as further described in Example 8, *infra*.

5 FIG. 7 provides a schematic diagram illustrating various recombinant fibronectin fragments used in Examples 9-11, *infra*.

FIG. 8 shows retrovirus binding to various fibronectin fragments, including to several recombinant fragments, as described
10 in Example 9, *infra*.

FIG. 9 demonstrates that heparin blocks retrovirus binding to fibronectin fragments, as described in Example 9, *infra*.

15 FIG. 10 shows the efficiency of retrovirus infection of murine hematopoietic cells in the presence of various fibronectin fragments, as further reported in Example 10, *infra*.

FIG. 11 compares the presence of hADA in mice engrafted with
20 bone marrow cells transduced by (i) the coculture method, (ii) supernatant infection on various fibronectin fragments, and (iii) supernatant infection on BSA, as described in Example 11, *infra*.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

For the purpose of promoting an understanding of the principles of the invention, reference will now be made to certain
5 embodiments thereof and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations, further modifications and such applications of the principles of the invention as illustrated herein being contemplated as would
10 normally occur to one skilled in the art to which the invention relates.

As indicated above, the present invention provides methods for increasing the frequency of transduction of viable cells by viruses
15 such as retroviruses. The invention also provides methods for efficient gene transfer into viable cells using recombinant retroviral vectors, methods for obtaining transduced cells, and methods and materials for achieving autologous and other cellular grafts.

20 One feature of the present invention is the discovery that fibronectin (FN), and fragments of fibronectin containing the CS-1 cell-adhesion domain of FN, significantly enhance retroviral-mediated gene transfer into cells such as hematopoietic cells, e.g. committed progenitors and primitive hematopoietic stem cells or
25 long-term culture-initiating cells (LTC-IC), carrying a fibronectin receptor and thereby exhibiting the capacity to bind to fibronectin

-13-

or fragments thereof. Advantageously, this increased efficiency makes cocultivation with virus-producing cells unnecessary. Other features of the invention capitalize on the discovery of a viral-binding domain of fibronectin located within the Heparin-II binding domain. This viral-binding domain can be used to localize virus particles in many applications, including for example in a broad range of constructs for delivering the virus to a target cell.

Recombinant viral vectors in accordance with certain preferred aspects of the present invention contain exogenous DNA and are non-pathogenic, i.e. replication-defective. These vectors efficiently transfer and precisely and stably integrate exogenous DNA into cellular DNA of host cells such as animal cells, particularly mammalian cells. For example, in the present invention a nucleotide sequence including a run of bases from the coding sequence of the gene of interest can be incorporated into a recombinant retroviral vector under the control of a suitable promoter to drive the gene, typically an exogenous promoter. In this regard, the exogenous DNA can contain DNA which has either been naturally or artificially produced, and can be from parts derived from heterologous sources, which parts may be naturally occurring or chemically synthesized molecules, and wherein those parts have been joined by ligation or other means known to the art. As indicated, the introduced nucleotide sequence will be under control of a promoter and thus will be generally downstream from the promoter. Stated alternatively, the promoter sequence will be generally upstream

-14-

(i.e., at the 5' end) of the coding sequence. In this vein, it is well known that there may or may not be other regulatory elements (e.g., enhancer sequences) which cooperate with the promoter and a transcriptional start codon to achieve transcription of the exogenous coding sequence. The phrase "under control of" contemplates the presence of such other elements as are necessary to achieve transcription of the introduced gene. Also, the recombinant DNA will preferably include a termination sequence downstream from the introduced coding sequence.

10

Retroviral vectors that include exogenous DNA providing a selectable marker or other selectable advantage can be used. For example, the vectors can contain one or more exogenous genes that provide resistance to various selection agents including antibiotics such as neomycin. Representative vectors which can be used in the invention include for example the N₂/ZipTKNEO vector (TKNEO) (titer: 1×10^5 G418^r cfu/ml on NIH 3T3 cells), the ZipPGK-hADA vector, and the ZipPGK-mADA vector all as previously reported by Moritz et al. (1993) *J. Exp. Med.* 178:529. In the TKNEO vector, neo phosphotransferase sequences are expressed in the sense orientation (relative to the 5' long terminal repeat-LTR) via the herpes simplex thymidine kinase promoter. This vector contains a selectable marker gene which provides neomycin resistance to facilitate the identification of transduced cells. In the ZipPGK-hADA vector, the human ADA ("hADA") cDNA is expressed in the sense orientation relative to the 5'LTR via the human phosphoglycerate

25

-15-

kinase (PGK) promoter. It contains only one expressible genetic sequence and lacks a dominant selectable marker. The ZipPGK-mADA (PGK-mADA) vector is identical to the ZipPGK-hADA vector except the human ADA cDNA has been replaced with murine ADA ("mADA") DNA. These and other viral vectors and techniques for their production are well known and their implementation and use in the present invention will be well within the skills of those practiced in the art given the disclosure herein.

10 Viral vectors used in the invention exhibit the capacity to bind to an amino acid sequence of the Heparin-II binding domain of fibronectin, including that of human fibronectin. As discussed in the passages which follow, although the present invention is not limited by any theory, it is believed that co-localization of the virus and the target cell via binding of the virus and cell to respective functional domains facilitates an enhancement in the transduction of the cell by the virus. In this regard, the capacity of a virus to bind to the amino acid sequence of the Heparin-II binding domain and thus to serve effectively in the invention can be readily ascertained using routine procedures such as those described in Examples 8 and 9 below. Generally speaking, these assays determine the extent to which virus particles are bound to immobilized polypeptides containing the Heparin-II binding domain, so as to resist washing from the immobilized polypeptide matrix. Briefly, for instance, a virus-containing supernatant can be incubated in a well containing immobilized polypeptide including the fibronectin Heparin-II

-16-

binding domain. The well is then extensively washed with physiologic saline buffer, after which target cells to the virus are incubated in the well to determine the level of infectious activity remaining in the well. The reduction in infectious activity, or titer, relative to the initial viral supernatant is assessed and compared to that of a similar control run (e.g. using a BSA-coated well). A significantly higher titer remaining in the Heparin-II domain containing well as compared to the control well signifies that the subject virus is suitable for use in aspects of the invention. To facilitate this screening procedure, the viral vector may contain a selectable marker gene, as discussed above.

Fragments of fibronectin for use in the invention can be of natural or synthetic origin, and can be prepared in substantial purity from naturally-occurring materials, for example as previously described by Ruoslahti et al. (1981) *J. Biol. Chem.* 256: 7277 ; Patel and Lodish (1986) *J. Cell. Biol.* 102:449; and Bernardi et al. (1987) *J. Cell. Biol.* 105:489. In this regard, reference herein to a substantially pure fibronectin or fibronectin fragments is intended to mean that they are essentially free from other proteins with which fibronectin naturally occurs. Substantially pure fibronectin or fibronectin fragments for use in the invention can also be recombinantly produced, for instance as generally described in U.S. Patent No. 5,198,423 issued March 30, 1993 to Taguchi et al. and assigned to Takara Shuzo Co., Ltd., Kyoto, Japan. In particular, the recombinant fragments identified in the Examples below as H-271, H-296, CH-

-17-

271, CH-296 and C-CS1, and methods for obtaining them, are described in detail in this '423 patent. The C274 fragment utilized in the Examples below was obtained as described in U.S. Patent No. 5,102,988. These fragments or fragments from which they can be
5 routinely derived are available by culturing *E. coli* deposited at the Fermentation Research Institute of the Agency of Industrial Science and Technology, Japan as FERM P-10721 (H-296), FERM BP-2799 (C-277 bound to H-271 via methionine), FERM BP-2800 (C-277 bound to H-296 via methionine), and FERM BP-2264 (H-271), as also
10 described in U.S. Patent No. 5,198,423. In addition, useful information as to fibronectin fragments utilizable herein or as to starting materials for such fragments may be found in Kimizuka et al., *J. Biochem.* 110, 284-291 (1991), which reports further as to the above-noted recombinant fragments; in *EMBO J.*, 4, 1755-1759
15 (1985), which reports the structure of the human fibronectin gene; and in *Biochemistry*, 25, 4936-4941 (1986), which reports on the Heparin-II binding domain of human fibronectin. Fibronectin fragments which contain both the CS-1 cell adhesion domain and the Heparin-II binding domain, for example as included in about a 30 or
20 35 kd fragment (30/35 FN) and in various recombinant fragments as reported in the Examples below, have been found to significantly enhance the efficiency of gene transfer into hematopoietic cells in work thus far, and are preferred for use in the invention. It will thus be understood that, broadly speaking, the fibronectin-related
25 polypeptide or polypeptides utilized in the invention will provide an amino acid sequence providing the cell-binding activity of the CS-1

-18-

cell adhesion domain of fibronectin as well as an amino acid sequence of the Heparin-II binding domain of fibronectin which binds the virus. The skilled artisan will recognize that the necessary cell- and virus-binding activities can be provided both by the native
5 amino acid sequences of these functional fibronectin domains and by amino acid sequences which differ from the native sequences yet are sufficiently similar to exhibit the cell-binding and viral-binding activities. These similar amino acid sequences will exhibit substantial sequence homology to their corresponding native
10 sequences, and can include those in which amino acids have been deleted, substituted for and/or modified while nonetheless providing an amino acid sequence with the desired cell-binding or viral-binding characteristic.

15 In this regard, the pertinent biotechnological arts have advanced to a state in which the deletion, substitution, addition or other modification of amino acids in the subject functional domains can be routinely performed. The resulting amino acid sequences can then be routinely screened for the desired cell-binding or viral-
20 binding activity. For example, viral-binding activity of mutant or modified forms of the Heparin-II-binding domain of fibronectin can be screened as generally discussed above and more specifically below in Examples 8 and 9, using virus incubation, wash, and viral titer assays to determine the retention of infectiousness compared to
25 a control. Given the teachings provided herein, these binding assays

-19-

will represent but routine experimentation to those working in this field.

Cell-binding to modified or mutant forms of the CS-1 cell
5 adhesion domain of fibronectin, or to other cell-binding polypeptides,
can likewise be assayed using conventional procedures. For example,
such procedures include those described in *Nature* 352: 438-441
(1991). Briefly, the cell-binding polypeptide is coated on plastic
dishes and the cell population to be assayed is overlaid in medium
10 for 30 minutes to 2 hours. After this incubation period, cells non-
adherent to the protein are retrieved, counted and assayed for
viability. Cells adherent to the polypeptide are also retrieved using
trypsin or cell dissociation buffer (e.g. Gibco), counted and viability
tested. In some cases, for example for hematopoietic colony forming
15 cells, the cells are further cultured for an additional 12-14 days to
ascertain the colony forming characteristics of the cells. The
percentage of adherent cells is then calculated and compared to
standard to a standard control such as bovine serum albumin (BSA)
coated plastic dishes. Substantial binding of the target cells to the
20 assayed polypeptide provides an indication that the polypeptide/cell
combination is suitable for the invention, and the polypeptide can be
coupled to the retroviral binding fragment from fibronectin to produce
a construct of the invention for enhancing the infection of the target
cells by the viral vector.

-20-

Pursuant to more specific aspects of the invention, the viral-binding polypeptide utilized to enhance transduction by retroviral vectors will comprise (i) a first amino acid sequence which corresponds to the Ala¹⁶⁹⁰ - Thr¹⁹⁶⁰ of the Heparin-II binding domain of human
5 fibronectin, which is represented by the formula (Seq. I.D. #1):

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr Ser
Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val
Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala
10 Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys Tyr
Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg Pro Ala Gln
Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro Pro Arg Arg Ala Arg Val
Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile Ser Trp Arg Thr Lys Thr Glu
Thr Ile Thr Gly Phe Gln Val Asp Ala Val Pro Ala Asn Gly Gln Thr Pro
15 Ile Gln Arg Thr Ile Sys Pro Asp Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln
Pro Gly Thr Asp Tyr Lys Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg
Ser Ser Pro Val Val Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn
Leu Arg Phe Leu Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro
Pro Arg Ala Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro
20 Pro Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu Lys
Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr;

or a sufficiently similar amino acid sequence thereto to exhibit the
25 ability to bind the retrovirus;

-21-

and (ii) a second amino acid sequence which corresponds to one portion of the IIICS binding domain of human fibronectin (the CS-1 cell binding domain); which is represented by the formula (Seq. I.D. #2):

5 Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu His Gly
Pro Glu Ile Leu Asp Val Pro Ser Thr;

or a sufficiently similar amino acid sequence thereto to exhibit the ability to bind hematopoietic cells such as primitive progenitor
10 and/or long term repopulating (stem) cells.

As mentioned previously, it will be understood that certain modifications and/or mutations of these native sequences are possible within the practice of the present invention, so long as the
15 resulting amino acid sequence is sufficiently similar to the native sequence to exhibit the ability to bind the virus (in the case of the Heparin-II-binding domain) and the ability to bind the target cells (in the case of the CS-1 domain).

20 One aspect of the invention provides a method of somatic gene therapy which involves *in vitro* cellular therapy and subsequent transplantation of target cells into a host, also known as "engraftment" of the host with the transduced target cells. Hematopoietic or other cells can be collected from a human or other
25 mammalian animal source using standard protocols. For example, the hematopoietic cells can be collected from bone marrow or

-22-

peripheral blood of a human donor or from human fetal umbilical cord blood. Once collected, the hematopoietic cells can optionally be treated by standard techniques to enrich them in stem cells and/or primitive progenitor cells. The hematopoietic cells can then be
5 suitably incubated, for instance on tissue culture plates. Optionally during this period, adherent-negative low density mononuclear cells can be prestimulated prior to retroviral infection. Prestimulation as known in the art and as used herein refers to the process of exposing cells to growth stimulating factors before exposure to
10 retroviruses. Such prestimulation has proven to improve the transduction of hematopoietic cells by retroviruses.

Subsequent to prestimulation, the cells can be harvested and incubated with fibronectin or fragments thereof as described herein
15 which enhance the frequency of cellular transduction by retroviruses. Preferably, the cells are incubated with purified and/or insoluble, e.g., immobilized fibronectin or fibronectin fragments. The cells can then be infected with the recombinant virus, for instance a retrovirus containing a gene for correcting an
20 enzyme or other protein deficiency or abnormality in the cells, in the presence of an amount of the fibronectin or fibronectin fragment effective to increase the frequency of transduction of the cells by the virus. The resulting transduced hematopoietic cells can then be conventionally introduced, e.g. intravenously, into an animal cellular
25 graft recipient, preferably an autologous donor but also including

-23-

allogeneic transplants, the latter especially where umbilical cord blood cells are used for the graft as discussed below.

Methods of the invention can be used in gene marking or gene therapy protocols for a variety of disorders including bone marrow disorders, including for example cancers, leukemias, disorders involving protein deficiencies or abnormalities, and therapies for modifying hematopoietic cells to improve resistance to other therapeutic protocols such as chemotherapy. Representative disorders with which the invention may be used thus include ADA deficiency, e.g. ADA-deficient SCID, pediatric acute myelogenous leukemia (AML), neuroblastoma, and adult AML and acute lymphocytic leukemia (ALL).

In one particularly preferred embodiment of the invention, the cells utilized for a cellular graft are obtained from human umbilical cord blood. Thus, human umbilical cord blood can be collected and enriched in viable primitive hematopoietic progenitor and/or stem cells, for example by obtaining an adherent-negative, low density, mononuclear cell population. This population is then optionally prestimulated, and incubated in the presence of a retroviral vector and immobilized and/or purified fibronectin or fibronectin fragments, to enhance the transduction efficiency of the cells by the vector. In this regard it has been found that the transduction of the primitive hematopoietic and/or stem cells from umbilical cord blood is greatly enhanced in the presence of the fibronectin or fibronectin

-24-

fragments, even though fibronectin does not constitute part of the ECM in cord blood and even though primitive progenitor and stem cells from cord blood have been characterized as different from those from bone marrow. In particular, the cord blood stem cell has been characterized as CD34⁺, HLA-DR⁺, whereas the stem cell from bone marrow has been characterized as CD34⁺, HLA-DR⁻. The Applicants' discovery that primitive progenitor cells from umbilical cord blood are effectively transduced in an enhanced fashion in the presence of the fibronectin or fibronectin fragments enables the use of a convenient and highly stem-cell-enriched source of hematopoietic cells. Moreover, evidence of successful engraftment of numerous patients with allogeneic transplants of cord blood enriched for primitive progenitor and stem cells, makes cord blood a highly preferred source for hematopoietic cells. See, Kohli-Kummer et al., *Brit. Haematol.* 85:419-422 (1993); Broxmeyer et al., *Blood Cell* 17:313-329 (1991); Gluckman et al., *Br. J. Haematol.* 45:557 (1980); Heidelberg: Springer-Verlag pp. 60-68 (1989); Wagner et al., *Blood* 79:1874-1881 (1992); and Wagner et al., *Blood* 82-86a (Abstract).

20

If desired, harvested transduced hematopoietic or other cells can be tested for transduction efficiency and gene expression. For instance, the significant improvements in retrovirus-mediated gene transfer provided by the invention are demonstrated in the specific Examples below, which describe several tests demonstrating high infection and gene transfer efficiency by retroviruses in the

25

-25-

presence of fibronectin or effective fibronectin fragments. In particular, murine hematopoietic cells infected with PGK-hADA retrovirus expressed high levels of the transferred ADA cDNA. Similarly, individual PGK-mADA virus infected human progenitor colonies expressed murine ADA levels up to 10-fold higher than the endogenous human ADA protein. Therefore, to stringently analyze transfer efficiency, progenitor colonies were considered transduced only if expression of the transferred mADA was equal to or greater than endogenous human ADA levels. High levels of expression of neo from the TKNEO vector were detected by G418 drug resistance, as an assay for neophosphotransferase (the neo gene product) activity.

As indicated above, methods of the present invention are advantageously conducted without the need for cocultivation in the presence of retroviral producer cells. Thus, in accordance with one aspect of the invention, the retroviral-mediated gene transfer can be carried out in the substantial absence of cells other than the target hematopoietic or other cells. For example, producer cells containing the retroviral vector plasmid can be cultured and supernatant collected. The retroviral-containing supernatant can then be utilized to infect the hematopoietic cells in the presence of the fibronectin and/or fibronectin fragments, which are preferably in immobilized form, e.g. coated on a substrate upon which the infection is carried out or otherwise in contact with the medium for infection. In this regard, any producer cells which produce high-titer helper-free

-26-

retroviruses are contemplated as suitable for use in the invention. These include, for example, packaging cells such as Psi-2, C2, PA12, PA317, and GP+envAM12, as well as many other packaging cell lines known in the art.

5

In accordance with other features of the invention, the strong virus binding to amino acids within the Heparin-II binding domain of fibronectin may be used for constructing delivery systems for viral therapy across a broad range of cell types. To this end, a
10 polypeptide including the retrovirus binding domain from fibronectin may be covalently coupled to any ligand which gives this construct specificity for the target cells. This approach will circumvent the prior necessity of constructing specific retrovirus cell lines for each target cell (Kasahara, N., A. M. Dozy, and Y. W. Kan.,
15 *Science*, Vol. 266, pp. 1373-1376 (1994) and Valsesia-Wittmann, S., A. Drynda, G. Deleage, M. Aumailley, J. M. Heard, O. Danos, G. Verdier, and F. L. Cosset, *J. Virol.*, Vol. 68, pp 4609-4619 (1994)). The specificity of the targeting construct may be provided by employing ligands including for example 1) cell adhesive protein, 2) hormones
20 or cytokines, 3) monoclonal antibodies to the target cells, 4) carbohydrates which bind the target cells (G. Ashwell, et al., *Annu. Rev. Biochem.*, Vol. 51, pp. 531-554 (1982)), 5) metabolites for the target cells, or 6) functional polypeptides which bind the target cells. The efficiency of the construct for gene delivery may be improved
25 by including several Heparin-II virus binding domains and therefore increasing the amount of viral particles delivered to the

-27-

target cells. For example, the cell-binding domain of human fibronectin which corresponds to Pro¹²³⁹ - Ser¹⁵¹⁵, as described in U.S. Patent No. 5,198,423, has been shown to bind to cells including BHK and B16-F10 cells (Kimizuka et al., J. Biochem. Vol. 110, pp. 285-291 (1991)). In addition, the Heparin-II domain itself has been shown to bind to fibroblasts, endothelial cells, and tumor cells. These polypeptide sequences may be coupled to the retrovirus binding domain from fibronectin to target predetermined cells for infection by retrovirus.

10

Exemplary applications in the hematopoietic system also include a construct of erythropoietin or G-CSF coupled to the retrovirus binding domain of fibronectin for targeting highly specific erythroid or granulocytic precursor cells, respectively. Another common application in accordance with the present invention will be to combine the retrovirus binding domain or domains with a ligand which specifically or predominantly binds to malignant cells. For example, it has been shown that *in vitro* and even *in vivo* growth of breast carcinoma cells can be influenced employing substances binding to receptors on the target cells like luteinizing hormone releasing derivatives, Emons, G. et al., *Hum. Reprod.* 9:1364-1379 (1994), oestrogens, Tolcher, A. W., *Oncol.* 8:39-43 (1994), or anti-oestrogens, Howell, A. et al., *Lancet* 345:29-30 (1995), progestogens or anti-progestogens, Klijn, F. G. et al, *Hum. Reprod.* 9 Suppl. 1:181-189 (1994); Griffiths, K. et al, *Semin. Oncol.* 21:672-687 (1994),

25

-28-

which will serve as ligands in constructs of the invention containing one or more virus binding domains from fibronectin. As further examples, thyroid (cancer) cells may be targeted highly specifically by using constructs with Jodid, and liver (cancer) cells may by
5 targeted by constructs containing HDL or parts thereof. Finally, constructs of monoclonal antibodies and the retrovirus-binding domain of fibronectin will allow the targeting of any cell and organ against which an antibody is available. A broad range of mammalian cell types are thus targetable by capitalizing upon the
10 ability of the retrovirus binding domain of fibrobnectin to bind and localize viral vectors.

Accordingly, another preferred embodiment of the invention involves the preparation of construct which can be used to enhance
15 the viral transduction of a target cell. The viral-binding amino acid sequence of the Heparin-II-binding domain of fibronectin is coupled to a ligand to which the target cell binds. As discussed above, the ligand may be, for example, a polypeptide from fibronectin or from another protein (including a cell adhesive protein, for example
20 laminin, collagen, vitronectin, osteopontin or thrombospondin), a hormone, a metabolite, an antibody (including monoclonal antibodies), or any other ligand exhibiting the capacity to bind, preferably with specificity, to the target cell. The resulting overall construct can be used in immobilized form in a fashion similar to

-29-

that used for the fibronectin polypeptides specifically exemplified in the Examples below.

Such constructs and cell-targeting approaches may be utilized *in vitro* as discussed above, and also in *in vivo* targeting of retroviruses, taking into account various factors such as the stability and specificity of the construct and the retrovirus construct interaction under physiological conditions. The specificity may also be improved by modifying the delivery system to localize delivery of the construct to the target cells, for instance catheterizing the portal vein for targeting liver cells.

It is contemplated that highly convenient retroviral-mediated DNA transfer will be carried out utilizing kits specially designed to practice methods of the invention. Accordingly, another aspect of the invention provides kits which include an amount of the substantially pure polypeptide or construct discussed above which enhances the transduction of target cells by retroviruses, along with an artificial substrate upon which the retroviral infection can be carried out. The polypeptide or other construct can be provided separately or coated upon the artificial substrate. In the case of infection protocols for human hematopoietic cells the kits will also include hematopoietic cell growth factors for cell prestimulation. In addition, the kits can include the recombinant retrovirus vectors as discussed above for the transduction. Generally speaking, the kits will include sterile packaging which secures these various kit components in spaced

-30-

relation from one another sufficient to prevent breakage of the components during handling of the kit. For example, it is a common practice to utilize molded plastic articles having multiple compartments or areas for holding the kit components in spaced
5 relation.

In order to promote a further understanding and appreciation of the invention, the following specific Examples are provided. It will be understood that these examples are illustrative and not
10 limiting in nature.

EXAMPLE 1

Gene Transfer into Bone Marrow Cells Using TKNEO

15 1.1. Preparation of Virus-Supernatant

GP+EnvAM 12 producer cells (see Markowitz et al. (1988) *Virology* 167:400) containing retroviral plasmid TKNEO vector were cultured in Iscove's Modified Dulbeccos Medium (IMDM, Gibco, Gaithersburg, MD) containing 10% fetal calf serum (FCS, Hyclone,
20 Logan, UT) and 100 units/ml penicillin and 100 microgram/ml streptomycin (P/S, both Gibco). Virus containing supernatant was collected by adding 10 ml of IMDM containing 20% FCS to confluent plates overnight. Harvested medium was filtered through 0.45 micron filters (Gelman Sciences, Ann Arbor, MI) and stored at -
25 80° C until used.

1.2. Preparation of fibronectin fragments

FN was purified from human plasma (Lifescience, Glenview, IL) as previously described in Ruoslahti et al., *Methods Enzymol.* 82:803-831 (1982), except that the gelatin-agarose column was washed with 1M urea prior to elution of FN with 4M urea. Purified FN was dialyzed extensively at 4°C against 10mM 3-(cyclohexylamino)-1-propane-sulfonic acid (CAPS), 150mM NaCl, 2mM CaCl₂ pH 11.0 and stored in aliquots at -80°C. The chymotryptic cell binding domain (CBD) (CS-1) and Heparin-II binding fragments of FN were purified as previously described (Ruoslahti et al. (1982), supra, Patel and Lodish, *J. Cell. Biol.* 102, pp. 449-456 (1986), and Bernardi et al., *J. Cell. Biol.* 105, pp. 489-498 (1987). Three major heparin-binding fragments (30kD, 35kD, and 42kD) were obtained in the 1M NaCl eluate from the heparin-agarose column. To further purify these heparin-binding fragments, the 1M NaCl eluate was dialyzed overnight at 4°C against 10mM Tris-HCl, pH 7.0 and passed over an anion exchange column (2ml DEAE sepharose fast flow (Pharmacia Fine Chemicals, Uppsala, Sweden)/mg of protein) that had been equilibrated with 10mM Tris-HCl pH 7.0. The 30/35kD fragments were collected in the unbound fraction while the 42kD fragment was eluted from the column with 100mM NaCl. From 500mg of FN, approximately 26mg of the 30/35kD fragments and 4mg of the 42kD fragment were obtained. The 42kD fragment, but not the 30/35kD fragments, were recognized by an antibody against the fibrin-binding domain, as

-32-

determined by western blotting technique. Also, the 42kD fragment binds to a fibrin-sepharose affinity column.

For use in the infection protocol, fibronectin fragments were
5 immobilized on 35 or 100 mm petri dishes (Falcon, Lincoln Park, NJ)
at a concentration of 75 pmol/cm² as described by Patel and Lodish
(1986), *supra*. Control plates were coated in analogous fashion with
2% (FN-free) bovine serum albumin (BSA, Boehringer Mannheim,
Mannheim, Germany).

10

1.3. Retroviral infection protocol

~~Bone marrow samples from healthy adult donors were collected~~
in tubes containing sterile, preservative-free sodium sulfate heparin
according to protocols approved by the Institutional Review Board of
15 Indiana University School of Medicine. Low density mononuclear
cells were prepared by centrifugation on Ficoll-Hypaque (density
1.077 g/ml, Pharmacia, Piscataway, NJ) for 45 minutes at 25°C.
Plastic adherent cells were removed from low density bone marrow
cells by an additional incubation on tissue culture plates for 4-16
20 hours at 37°C in 5% CO₂ in IMDM with 2% FCS.

Adherent-negative low density mononuclear cells were
prestimulated prior to retroviral infection as described previously
by Luskey et al. (1992) *Blood* 80:396, for 48 hours at 37°C and 5%
25 CO₂ in IMDM containing 20% FCS, 100 U/ml rhIL-6, 100 ng/ml rhSCF

-33-

(both Amgen, Thousand Oaks, CA), and P/S at a cell density of 1×10^6 cells/ml in petri dishes. Prestimulated cells were harvested by vigorously pipetting to remove cells loosely adherent to the plastic.

5 Prestimulated cells (5×10^5 cells/ml) were incubated for 6 hours on plates coated with BSA (control plates) or fibronectin or fragments thereof (subjected to UV radiation to better adhere the proteins to the plastic plate) and then infected with virus supernatant in the presence of growth factors (as above) and 7.5
10 micrograms/ml polybrene (Aldrich Chemical, Milwaukee, WI). Virus supernatant was replaced (including growth factors and 5.0 microgram/ml polybrene) after 2 hours and cells were incubated for an additional 12 to 24 hours. Non-adherent cells were re-added with each media change.

15

Following the infection protocol, non-adherent cells were decanted and adherent hematopoietic cells were collected from the cultures using Cell Dissociation Buffer (CDB) (enzyme free/PBS based, Gibco) according to the manufacturer's instructions. The adherent
20 cells were added to the non-adherent fraction, washed twice and counted. Harvested cells were either plated in clonogenic methylcellulose progenitor assays or long term bone marrow cultures.

1.4. Long term bone marrow cultures

25 ETC-IC (human stem cell) assays were performed according to previously described methods with slight modifications. Sutherland

-34-

et al. *Blood* 74:1563 (1989). Briefly, $0.5-1 \times 10^6$ infected cells were seeded in long term bone marrow cultures (LTMC) on confluent, pre-irradiated (as above) allogenic human bone marrow fibroblasts (BMF) in 5 ml IMDM containing 10% FCS, 10% horse serum (Sigma) and P/S, 1×10^{-5} M hydrocortisone (Upjohn, Kalamazoo, MI), and 320 mosmol sodium chloride in 6 well tissue culture plates (Costar, Cambridge, MA). LTMC were incubated at 33°C in 5% CO₂ and fed weekly by removal of 50% of the media and non-adherent cells. After five weeks, LTC-IC cultures were sacrificed by using CDB to remove adherent hematopoietic cells from BMF. Both non-adherent and adherent hematopoietic cells were combined and plated in methylcellulose to obtain colonies derived from LTC-IC.

1.5. Clonogenic methylcellulose assays

Methylcellulose assays were performed as previously described by Toksoz et al. *Proc. Natl. Acad. Sci., USA*, Vol. 89, p 7350 (1992), with minor modifications. Briefly, $2-5 \times 10^4$ infected adult bone marrow cells were plated with 5 units/ml erythropoietin (Epo, Amgen), 100 ng/ml rhSCF, 10 ng/ml rhIL-3 (Genzyme, Cambridge, MA) in 1 ml of 2.4% IMDM methylcellulose (Fluka, Ronkonkoma, NY) containing 25% FCS, 10% human plasma, 10^{-5} M beta-mercaptoethanol (Sigma), and P/S. Cultures were incubated at 37°C in 5% CO₂/95% air and colonies (>50 cells) were scored by viewing on an inverted microscope on day 13 as CFU-GM (containing

granulocytes and macrophages), CFU-Mix (containing myeloid and erythroid elements), or BFU-E (containing only erythroid elements).

1.6. Analysis of retroviral infection

5 Efficiency of infection with the TKNEO virus was analyzed by determining the percent of methylcellulose colonies resistant to 1.5 mg/ml (dry powder, Gibco) G418 on day 13. Mock infections were performed in each experiment by incubating bone marrow on the GP+EnvAM 12 packaging line making no recombinant virus. Culture
10 of these mock infected cells with 1.5 mg/ml G418 consistently demonstrated <1% background colonies.

1.7. Gene transfer efficiency into committed progenitor cells

15

Transduction efficiency was compared by infecting bone marrow cells while plated on 30/35 FN- or BSA-coated dishes. No difference in the number of colonies obtained after infection without selection was observed between these conditions. FIG. 2
20 demonstrates the percentage of G418^r colonies after infection. A higher percentage of G418^r colonies was noted on 30/35 FN from all types of progenitors, including those derived from lineage-restricted (BFU-E and CFU-GM) as well as multilineage (CFU-Mix) progenitor cells. Infection into all committed progenitors was increased 9-fold
25 on 30/35 FN versus BSA.

1.8. Gene transfer efficiency into long term culture-initiating cells

Gene transfer into LTC-IC was assessed using the TKNEO vector.
5 Gene transfer into LTC-IC derived colonies was only detected after infection on 30/35 FN (16% G418^r vs 0% G418^r colonies, 30/35 FN vs BSA).

10 1.9. Specificity of 30/35 FN effects on infection efficiency of hematopoietic cells

To determine the specificity of increased gene transfer efficiency seen on 30/35 FN, infection with TKNEO was performed on plates coated with BSA, 30/35 FN, intact fibronectin, a 115 kd FN
15 fragment containing the central cell-binding domain (CBD) containing the RGDS tetrapeptide sequence, and a 42 kd C-terminal FN fragment (42FN) characterized by the Heparin-II binding domain but lacking the CS-1 sequence (FIG. 1). Infection on BSA yielded $3 \pm 1\%$ G418^r BFU-E, $1 \pm 1\%$ G418^r CFU-GM, and $0 \pm 0\%$ G418^r CFU-MIX.
20 No significant increase in the proportion of G418^r colonies were noted on CBD, while slightly higher infection of BFU-E ($6.0 \pm 1\%$) were seen on 42 FN (FIG. 3). However, intact FN promoted increased gene transfer into all committed progenitors. The percentage of G418^r colonies after infection on intact FN were less than on 30/35
25 FN in all lineages, including BFU-E (16 ± 2 vs. $24 \pm 4\%$), CFU-GM (5 ± 2 vs $20 \pm 4\%$) and CFU-Mix (6 ± 1 vs 9 ± 1 ; intact FN vs 30/35 FN, respectively).

EXAMPLE 2

Gene Transfer into Bone Marrow Cells Using PGK-mADA

5 2.1. General Procedures

PGK-mADA virus supernatant was prepared as described for TKNEO in Example 1. Chymotryptic fragments of fibronectin (FIG. 1) were prepared as previously described in Example 1 and the retroviral infection protocol of Example 1 was followed. LTC-IC
10 (human stem cells) assays and Methylcellulose assays were performed according to Example 1.

2.2. Analysis of retroviral infection

Efficiency of infection with the PGK-mADA vector was
15 determined by protein analysis using ADA isoenzyme electrophoresis. Analysis of individual progenitor colonies was performed as previously described by Moritz (1993) and Lim et al. (1989) *Proc. Natl. Acad. Sci., USA*, Vol. 86, p 8892. To stringently analyze transfer efficiency, only colonies expressing mADA at the
20 same or a higher level than endogenous human ADA were considered transduced. For analysis of pooled colonies, colonies picked out of methylcellulose culture were combined in 1.5 ml microtubes (Rainin, Woburn, MA), washed with warm medium and phosphate buffered saline (PBS), centrifuged and stored at -20°C.
25 For ADA analysis, cells were lysed in 5 microliter of lysis buffer by repeated freezing-thawing cycles and isoenzyme electrophoresis was performed as previously described.

2.3. Gene transfer efficiency into committed progenitor cells

5 Transduction efficiency was compared by infecting bone marrow cells while plated on 30/35 FN- of BSA-coated dishes. No difference in the number of colonies obtained after infection without selection was observed between these conditions. As shown in Table 1, infection efficiency into all committed progenitors was
10 substantially increased on 30/35 FN vs BSA. As expected with the high titer ($\sim 1 \times 10^7$ virions/ml) vector, the transduction efficiency of committed progenitors was extremely high. Referring to Table I, infection of bone marrow on 30/35 FN with PGK-mADA yielded nearly 100% transduction of committed progenitors in two separate
15 experiments.

TABLE 1

Infection efficiency of committed human
progenitor cells on fibronectin 30/35 fragments
using the PGK-mADA vector

EXPERIMENT	BSA	30/35FN
Exp 1	1/18*	13/14
Exp 2	2/13	12/13

* number of mADA expressing colonies/total colonies analyzed

2.4. Gene transfer efficiency into long term culture-initiating cells

In four independent experiments performed with PGK-mADA a significant proportion of progenitor colonies derived from 5 week old LTMC (i.e. LTC-IC derived colonies) expressed the transferred murine ADA gene. Expression ranged from 2/12 (17%) to 6/6 (100%) of analyzed colonies (Table 2). Expression of the introduced mADA gene exceeded or at least equaled the amount of endogenous human ADA activity in all colonies considered positive. Infection efficiency for PGK-mADA was higher than for TKNEO. As shown in Table 2, infection of bone marrow on 30/35 FN with PGK-mADA yielded nearly 100% transduction of committed progenitors in two separate experiments.

-40-

TABLE 2

Infection efficiency of human long term culture
initiating cell (LTC-IC) using the PGK-mADA vector

EXPERIMENT	BSA	30/35FN
Exp 1	0/14*	10/19
Exp 2	N/A	2/12
Exp 3	0/4	3/5
Exp 4	0/4	6/6
Total	0/22	21/42

5 * number of mADA positive colonies/total colonies analyzed;
N/A: not analyzed

2.5. Specificity of 30/35 FN effects on infection efficiency of hematopoietic cells

10

Gene transfer efficiency into LTC-IC was increased on 30/35 FN. Due to the relatively small size of these secondary LTC-IC derived colonies, the ability to perform protein analysis on single colonies was limited. After infection with PGK-mADA on BSA, intact
15 fibronectin and 42 FN 0/6, 0/4, and 0/3 LTC-IC-derived colonies, respectively, demonstrated expression of murine ADA, while 3/5 LTC-IC-derived colonies infected on 30/35 FN expressed mADA. In addition, when multiple LTC-IC-derived colonies were pooled before analysis in two additional experiments, mADA expression was
20 detected only after infection on 30/35 FN and to a lesser degree on intact FN, but not on 42FN or BSA.

-41-

EXAMPLE 3
Gene Transfer into Bone Marrow
Cells Using PGK-hADA

5

3.1. General Procedure

PGK-hADA virus supernatant is prepared as described for TKNEO in Example 1. Chymotryptic fragments of fibronectin (FIG. 1) are prepared as previously described in Example 1 and the
10 retroviral infection protocol of Example 1 was followed. LTC-IC and methylcellulose assays were performed as described in Example 1.

3.2. Analysis of retroviral infection

For analysis of pooled colonies, colonies picked out of
15 methylcellulose culture are combined in 1.5 ml microtubes (Rainin, Woburn, MA), washed with warm medium and PBS, centrifuged and stored at -20°C. For ADA analysis, cells are lysed in 5 microliter of lysis buffer by repeated freezing-thawing cycles and isoenzyme electrophoresis is performed as previously described.

20

EXAMPLE 4
Gene Transfer into Cord Blood Cells Using TKNEO

4.1. General Procedure

25 TKNEO virus supernatant and chymotryptic fragments of fibronectin (FIG. 1) were prepared as previously described in Example 1. The retroviral infection protocol in Example 1 was

-42-

followed except that umbilical cord blood from normal, full term newborn infants was collected in tubes containing heparin according to protocols approved by the Institutional Review Board of Indiana University School of Medicine, and used instead of the bone marrow cells. LTC-IC (human stem cell) and methylcellulose assays were performed according to Example 1.

4.2. Gene transfer efficiency into committed progenitors

Infection on FN30/35 was more than four times increased compared to BSA in three separate experiments (Table 3).

TABLE 3

Infection Efficiency of Cord Blood Progenitor Cells Using 30/35 FN Fragment and TKNEO Vector

BSA	12 \pm 17
30/35	55 \pm 16

EXAMPLE 5

Gene Transfer into Cord Blood Cells Using PGK-mADA

5.1. General Procedure

PGK-mADA virus supernatant and chymotryptic fragments of fibronectin (FIG. 1) were prepared as previously described in Example 1. The retroviral infection protocol in Example 1 was

-43-

followed except that cord blood from normal, full term newborn infants was collected in tubes containing heparin according to protocols approved by the Institutional Review Board of Indiana University School of Medicine. LTC-IC and methylcellulose assays
5 were performed according to Example 1.

5.2. Gene transfer efficiency into long-term culture initiating cells

10 Using the higher titer PGK-mADA vector, analysis of LTC-IC-derived colonies demonstrated high level expression of the introduced mADA cDNA only from cultures established from cord blood-infected using supernatant on FN30/35. Little expression of
15 mADA was detected in LTC-IC-derived colonies infected in BSA control plates.

The results shown in Examples 4 and 5 demonstrate that improved infection efficiency using FN30/35 can also be achieved when using cord blood progenitor and stem cells.

20

EXAMPLE 6 Gene Transfer into Cord Blood Cells Using PGK-hADA

PGK-hADA virus supernatant and chymotryptic fragments of
25 fibronectin (FIG. 1) are prepared as described for TKNEO in Example 1. The retroviral infection protocol in Example 1 is followed except that cord blood from normal, full term newborn infants is collected in tubes containing heparin according to protocols approved by the

-44-

Institutional Review Board of Indiana University School of Medicine, and used instead of the bone marrow cells. LTC-IC and methylcellulose assays are performed according to Example 1.

5

EXAMPLES 7-11

Retroviral vectors and producer cell lines
For Examples 7-11.

For Examples 7-11, two retrovirus-producing packaging cell
 10 lines were employed: the ecotropic GP + E86 (Markowitz, D., S. Goff, and A. Bank, *J. Virol.*, Vol. 62, pp 1120-1124 (1988)) and the amphotropic GP + envAM12 cell lines (Markowitz, D., S. Goff, and A. Bank, *Virology*, Vol. 167, pp 400-406 (1988)), respectively. The
 retroviral vectors and producer clones used in studies described
 15 here are listed in Table 1.

TABLE 4

VECTOR	PRODUCER/clone	cDNA expressed
PGK-hADA	GP+E86/EPHA-5	human ADA
PM5neo	GP+E86/EAL2a	neo phosphotransferase, LAC-Z
TKNeo	GP+E86/TKNeo	neo phosphotransferase
PGK-mADA	GP+EnvAM12/55/6	murine ADA

All cell lines were cultured in Dulbecco's modified Eagles
 20 medium (DME, Gibco, Grand Island, NY) containing 10% fetal calf serum (FCS, Hyclone, Logan, UT) and 100 units/ml penicillin and 100 µg/ml streptomycin (P/S, both Gibco) except for EAL2a cells which

-45-

were grown in DME-F12 (Gibco) with 10% FCS plus P/S. Virus containing supernatant was collected by adding 10 ml of alpha-minimal essential medium (α MEM, Gibco) for murine cells or Iscove's Dulbecco Medium (IMDM, Gibco) for human cells each
5 containing 10% FCS plus P/S to confluent 10cm plates overnight. Harvested medium was filtered through 0.45 micron filters (Gelman Sciences, Ann Arbor, MI) and stored at -80° until used.

EXAMPLE 7

10 Transduction of primary murine hematopoietic cells

7.1. Experimental

For studies with murine cells, bone marrow was harvested from femurs and tibiae of 6 to 8 week old C3H/HeJ mice 2 days following
15 administration of 150 mg/kg 5-fluorouracil (SoloPack Laboratories, Franklin Park, IL) (Lim, B., J. F. Apperley, S. H. Orkin, and D. A. Williams, *Proc. Natl. Acad. Sci. USA*, Vol. 86, pp 8892-8896 (1989)). Cells were prestimulated at a concentration of 5×10^5 cells/ml in
IMDM/20% FCS plus P/S with 100 ng/ml rat recombinant stem cell
20 factor (rrSCF; Amgen, Thousands Oaks, CA) and 100 units/ml recombinant human interleukin-6 (rhIL-6; Pepro Tech Inc., Rock Hill, NJ) for 48 hours (Luskey, B. D., M. Rosenblatt, K. Zsebo, and D. A. Williams, *Blood*, Vol. 80, pp 396-402 (1992)). Subsequently, gene
transfer efficiency with the PGK-hADA vector produced by EPHA-5
25 producer cells was compared using three different infection protocols: 1) supernatant infection; 2) supernatant infection on FN

30/35; 3) cocultivation on EPHA-5 producer cells. Therefore, 100mm bacterial dishes were coated with $2.5 \mu\text{g}/\text{cm}^2$ FN 30/35 (equivalent to $75 \text{ pmol}/\text{cm}^2$) dissolved in 5 ml phosphate buffered saline (PBS; Gibco) for 1 hour at room temperature under UV light with the dish lid open and for another hour with the dish lid closed. After blocking with 2% bovine serum albumin (BSA, Fraction V; Boehringer Mannheim, Indianapolis, IN) for 30 minutes at room temperature, dishes were washed once with Hank's Balanced Salt Solution (HBSS) supplemented with 2.5% (v/v) 1M Hepes (both Gibco). For supernatant infection, dishes were coated with BSA only. 5×10^6 prestimulated donor cells were incubated with 10 ml of virus supernatant obtained from EPHA-5 cells as described above supplemented with 100 U/ml rhIL-6, 100 ng/ml hrSCF and $7.5 \mu\text{g}/\text{ml}$ polybrene. Non-adherent cells were collected and re-added with the fresh virus supernatant. For co-culture, EPHA-5 cells in 4 ml medium were incubated with $10 \mu\text{g}/\text{ml}$ mitomycin C for 2 hours at 37°C , washed, trypsinized and seeded on 100mm tissue culture dishes at a concentration of 3×10^6 cells in 10 ml $\alpha\text{MEM}/20\%$ FCS plus P/S. The next day, 5×10^6 prestimulated bone marrow cells with 100 U/ml rhIL-6, 100 ng/ml rrSCF and $4 \mu\text{g}/\text{ml}$ polybrene were added for 48 hours. Following the infection protocol, non-adherent cells were decanted and adherent hematopoietic cells were collected from the cultures using Cell Dissociation Buffer (CDB) (enzyme free/PBS based, Gibco) according to the manufacturer's instructions. The adherent cells were added to the non-adherent fraction, washed

-47-

twice, and suspended in approximately 1 ml of HBSS/Hepes. The total cells obtained from 5×10^6 prestimulated cells were injected into the tail veins of three recipient mice which had been subjected to lethal total body irradiation (with 700 plus 400 cGy, ^{137}Cs -source) (Luskey, B. D., M. Rosenblatt, K. Zsebo, and D. A. Williams, *Blood*, Vol. 80, pp 396-402 (1992)). The transduction of hematopoietic stem cells was analyzed by examination of reconstituted mice for the expression of the introduced human ADA cDNA. This ADA isoenzyme analysis was performed in transplanted mice by examining peripheral blood cells for the presence of the hADA protein by cellulose acetate *in situ* enzyme analysis (Lim, B., D. A. Williams, and S. H. Orkin, *Mol. Cell. Biol.*, Vol. 7, pp 3459-3465 (1987)). Examination was performed beginning 4 months post-transplant and was repeated monthly.

15

7.2 Results

Long-term bone marrow reconstitution of mice with genetically manipulated hematopoietic stem cells is generally accepted as adequate to determine the efficiency of stem cell transduction after a period of 4 months post-transplant. Analysis of recipients of transduced bone marrow after 7 months by isoenzyme analysis revealed that: 1) human ADA cDNA expression was present using either co-culture or supernatant infection on FN 30/35 but absent in the group transplanted after supernatant infection without FN 30/35 and that; 2) the levels of expression were comparable for the co-culture and FN 30/35 groups. As shown in Figure 4, lanes 2-4,

25

-48-

three mice transplanted with bone marrow transduced by co-culture on EPHA-5 cells demonstrated easily detectable human ADA. Similar levels of human ADA were detected in three mice transplanted with hematopoietic cells transduced by supernatant infection of FN 20/35 (Figure 4, lanes 5-7). In contrast, no human ADA was detected in three mice transplanted with hematopoietic cells transduced by supernatant infection on BSA (Figure 4, lanes 8-10). Controls for the location of human ADA are shown in lanes 1 and 12 and murine ADA in lane 11 of Figure 4. The murine band in lanes 2-10 reveals that equal amounts of protein were loaded. These data demonstrate that transduction of long-term reconstituting hematopoietic stem cells by supernatant infection on FN 30/35 is equivalent to co-culture and far superior to supernatant infection without FN 30/35.

15

EXAMPLE 8

Mechanism Of Improved Transduction By Retrovirus Vectors Binding To FN 30/35

20 8.1. Experimental

To test whether increased transduction is the result of co-localization of virus and hematopoietic cells, we analyzed whether recombinant retroviral particles demonstrate binding to FN 30/35. Therefore, FN 30/35-coated plates were preincubated with supernatant containing TKNeo virus for 30 minutes and thereafter extensively washed. The viral titer of supernatant was determined using NIH/3T3 cells according to standard procedures (Markowitz,

25

-49-

D., S. Goff, and A. Bank, *J. Virol.*, Vol. 62, pp 1120-1124 (1988)). Briefly, 3T3 cells were plated at a concentration of 1000 cells/well in a 6-well tissue culture plate and grown overnight. Serial dilutions of virus supernatant were added to each well with 7.5 μ /ml polybrene and incubated for 2.5 hours at 37°C after which 2 ml of medium was added. After 24 hours, the medium was replaced with medium containing G418 (0.75 mg/ml, dry powder, Gibco) and the plates incubated for 10-12 days. The G418-resistant colonies (G418^r) were stained after 10-12 days and scored. The number of colonies/well multiplied by the dilution of virus supernatant was used as the infectious particles (cfu)/ml of supernatant. We assessed/"titered" the amount of retroviral particles remaining on FN 30/35-coated or BSA-coated 35mm plates after preincubation with virus supernatant and intensive washing by adding 1000 NIH/3T3 per 35mm bacteriologic dish cells plus polybrene. Twenty-four hours later, cultures were fed with medium containing 0.75 mg/ml G418 (dry powder) and the cells further incubated for 10-12 days. Following this incubation, the presence of adherent virus was quantitated by enumerating G418-resistant NIH/3T3 colonies.

20

To assess whether virus binding to FN 30/35 occurs in a dose-dependent fashion, the above experiments were repeated with increasing concentrations of FN 30/35 coating the dishes. Therefore, 35 mm bacteriologic dishes were coated with 1, 4, 10 and 20 μ g/cm² FN 30/35 as described above. A 1:50 dilution of a TKNeo virus stock previously titered at 1×10^4 infectious particles/ml was incubated on

25

-50-

FN 30/35-coated plates for 30 minutes. After intensive washing, 2000 NIH/3T3 cells were added to each well. Selection was carried out as above and G418-resistant NIH/3T3 colonies counted after 10 days of selection.

5

8.2. Results

Figure 5 sets forth the results of one of three representative experiments. Using TKNeo supernatant, retroviral titers measured by G418^r colonies in NIH/3T3 cells were reduced by more than 3
10 logs (4×10^3 to 0) on BSA-coated plates, while titer reduction was only 1 log on plates coated with 30/35 FN. These data demonstrate that retrovirus quantitatively binds to FN 30/35 but does not bind
to dishes coated with BSA (control dishes). Figure 6 shows that
increased numbers of G418-resistant colonies were detected when
15 virus-containing supernatant was incubated on plates coated with increased concentrations of FN 30/35. Therefore, virus binding to FN 30/35 occurs in a dose-dependent fashion.

20

EXAMPLE 9

Virus Binding To Recombinant Fibronectin Fragments

9.1. Experimental

Kimizuka et al. have previously reported the expression of
25 cloned FN DNA sequences in E. coli (Kimizuka, F., Y. Taguchi, Y. Ohdate, Y. Kawase, T. Shimojo, D. Hashino, I. Kato, K. Sekiguchi, and K. Titani, *J. Biochem.*, Vol. 110, pp 284-291 (1991)). Cloned and

-51-

chimeric peptides include one or a combination of several important sequences in fibronectin known to participate in cell adhesion (including RGDS, CS-1 and heparin-binding site), see Figure 7. To analyze whether retrovirus can bind to these recombinant FN fragments, 3T3 cell colony formation assays were repeated on plates coated with the recombinant fragments C-274, H-271, H-296, CH-271, CH-296, and C-CS1 as well as FN 30/35 as a positive control, using two different dilutions (1:10 and 1:100) of the frozen retrovirus TKNeo stock with 1×10^4 infectious particles/ml. FN fragments were used at a concentration of 120-130 pmol/cm² (equivalent to 4 $\mu\text{g}/\text{cm}^2$ for C-274, H-271, H-296, C-CS1, FN 30/35 and 8 $\mu\text{g}/\text{cm}^2$ for CH-271 and CH-296). Briefly, plates were coated, virus was added, plates were extensively washed, NIH/3T3 cells were added for 24 hours and then grown in selection medium for 10 days, subsequently colonies were stained and counted.

9.2. Results

Figure 8 demonstrates that the number of the G418-resistant colonies (and therefore virus adhesion) was increased in fragments H-271, H-296, CH-271 and CH-296. Furthermore, it shows that the amount of virus bound was roughly comparable between these recombinant fragments and FN 30/35, although in this work the CH-271 fragment exhibited the highest level of virus binding. Common to all of these 5 FN fragments are the type III repeats 12-14 which contain the high-affinity heparin-binding site (Ruoslahti, E., *Ann. Rev. Biochem.*, Vol. 57, pp 375-413 (1988) and Kimizuka, F., Y.

-52-

Taguchi, Y. Ohdate, Y. Kawase, T. Shimojo, K. Hashino, I. Kato, K. Sekiguchi, and K. Titani, *J. Biochem.*, Vol. 110, pp 284-291 (1991)) probably located in repeat 13 (Kimizuka, F., Y. Taguchi, Y. Ohdate, Y. Kawase, T. Shimojo, K. Hashino, I. Kato, K. Sekiguchi, and K. Titani, *J. Biochem.*, Vol. 110, pp 284-291 (1991)). This suggests that virus binding is occurring via this known adhesion site. This was evidenced by pre-incubating dishes coated with 4 $\mu\text{g}/\text{cm}^2$ CH-271 with increasing concentrations (10-1000 $\mu\text{g}/\text{ml}$) of heparin sulfate, a highly charged molecule known to inhibit cell binding to the heparin-binding site. As seen in Figure 9, the number of G418-resistant colonies is decreased following pre-incubation of CH-271 with increasing concentrations of heparin sulfate. These data suggest that virus binding to FN is mediated through the high affinity heparin-binding site located immediately adjacent to the CS-1 site in the carboxyl-terminal domains of FN.

EXAMPLE 10

Transduction Of Hematopoietic Cells On Recombinant Fibronectin Fragments

10.1. Experimental

To analyze whether the increased transduction of hematopoietic cells described previously on FN 30/35 could also be seen with recombinant FN fragments, we assessed the transduction efficiency of supernatant infections *in vitro* using high proliferative potential-colony forming cell (HPP-CFC) assays. By employing EAL2a vectors,

-53-

we compared the influence of various recombinant FN fragments versus FN 30/35 supernatant infection on BSA on transduction of hematopoietic cells using growth of G418-resistant colonies as an indicator of gene transfer. Furthermore, we compared the ability of virus particles already adherent to FN fragments (versus supernatant virus) to transduce hematopoietic cells. 0.5 to 1×10^6 prestimulated bone marrow cells were incubated on 35mm FN-coated petri dishes in 1-2 ml of EAL2a virus containing supernatant with growth factors and 5 μ g/ml polybrene as discussed above. To assess transduction of hematopoietic cells by virus bound to FN fragments, 35 mm FN-coated dishes incubated with virus-containing supernatant were washed three times with 2 ml PBS each. Subsequently, 0.5 to 1×10^6 prestimulated bone marrow cells were added in 2 ml of medium supplemented with growth factors and polybrene. 22 hours later, cells were harvested and plated in HPP-CFC assays with and without 1.5 mg/ml G418 as described (Bradley, T. R. and D. Metcalf, *Aust. J. Exp. Biol. Med. Sci.*, Vol. 44, pp 287-293 (1966)). The cultures were incubated for 14 days in 7% CO₂ at 33° C and the gene transfer efficiency was calculated as the percentage of G418 resistant colonies.

10.2. Results

Transduction of primitive hematopoietic cells via supernatant infection (Figure 10) was significantly higher than supernatant infection on BSA for all fragments which included the heparin-binding site (HBS) and at least one more active cell adhesion site

-54-

(solid bars). Transduction efficacy of the recombinant fragments CH-271, H-296, CH-296 and C-CS1 was similar to the effect of FN 30/35, all three fragments which include both the heparin-binding and the CS-1 site. In all other cases the transduction was
5 dramatically reduced. These data demonstrate that the increased transduction of primitive hematopoietic cells previously shown on FN 30/35 can be replicated on recombinant FN fragments. It further demonstrates that virus directly bound to fibronectin is capable of genetic transduction of hematopoietic cells. Finally it confirms the
10 utility of the presence of both the CS-1 and the heparin binding site for transduction of primitive hematopoietic precursor (stem) cells.

EXAMPLE 11

15 Long-Term Bone Marrow Reconstitution Of Mice Using Transduction Of Murine Donor Cells On Recombinant Fibronectin Fragments

11.1. Experimental

20 We repeated the above *in vitro* studies (from Example 10) for primitive hematopoietic progenitor cells comparing supernatant infection on BSA vs FN 30/35 versus recombinant FN fragments versus coculture using bone marrow transplantation to analyze effects on reconstituting hematopoietic stem cells. Briefly, lethally
25 irradiated mice were injected with donor cells which were transduced with the EPHA-5 vectors containing the human ADA

-55-

cDNA. After 1 month, gene transfer efficacy was analyzed from peripheral blood in ADA isoenzyme assays.

11.2. Results

5 Figure 11 clearly shows the fibronectin fragment H-296 containing both the heparin binding site and the CS-1 yields similar results to FN 30/35 and coculture. Fragments which do not contain both these sites are less effective in transducing a transplantable hematopoietic cell. These data demonstrate that co-localization of
10 primitive hematopoietic/stem cells and retrovirus bound to recombinant FN fragments containing both the CS-1 and the heparin binding sites effectively transduces transplantable hematopoietic cells.

15 While the invention has been illustrated and described in detail in the foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiment has been described and that all changes and modifications that come within the spirit of the
20 invention are desired to be protected.

All publications cited herein are hereby incorporated by reference in their entirety as if each had been individually incorporated by reference and fully set forth.

-56-

What is claimed is:

1. A method for increasing the frequency of transduction of viable hematopoietic cells by a replication-defective recombinant retrovirus vector, comprising infecting viable hematopoietic cells with a replication-defective recombinant retrovirus vector in the presence of substantially pure fibronectin, substantially pure fibronectin fragments, or a mixture thereof, so as to increase the frequency of transduction of the hematopoietic cells by the retrovirus vector.

2. The method of claim 1 wherein the hematopoietic cells have a protein deficiency or abnormality and the recombinant retrovirus vector includes an exogenous gene encoding the protein.

15

3. The method of claim 2 wherein the exogenous gene is a gene encoding adenosine deaminase.

4. The method of claim 3 wherein the exogenous gene is a gene encoding human adenosine deaminase.

5. The method of claim 1 wherein the cells are infected with the retrovirus vector in the presence of a fibronectin fragment containing an amino acid sequence which provides the cell-binding activity of the CS-1 domain and an amino acid sequence which provides the retrovirus binding activity of the Heparin-II domain.

25

-57-

6. The method of claim 1 wherein the hematopoietic cells comprise human stem cells.

5 7. The method of claim 6 wherein the hematopoietic cells are characterized as adherent-negative, low density, mononuclear cells.

8. A method for producing transduced hematopoietic cells,
10 comprising:

infected viable hematopoietic cells in culture with a
~~replication-defective recombinant retrovirus~~ in the presence of
immobilized fibronectin, immobilized fibronectin fragments, or an
immobilized mixture thereof, to produce transduced hematopoietic
15 cells.

9. The method of claim 8 which includes harvesting the transduced hematopoietic cells.

20 10. The method of claim 8 wherein the hematopoietic cells have a protein deficiency or abnormality and the recombinant retrovirus vector includes an exogenous gene encoding the protein.

11. The method of claim 8 wherein the hematopoietic cells
25 have an enzyme deficiency or abnormality and the exogenous gene is a gene encoding the enzyme.

-58-

12. The method of claim 11 wherein the hematopoietic cells are human hematopoietic cells having an enzyme deficiency or abnormality and the exogenous gene is a human gene encoding the
5 enzyme.

13. The method of claim 11 wherein the hematopoietic cells have an adenosine deaminase deficiency and the exogenous gene encodes adenosine deaminase.

10

14. The method of claim 12 wherein the human
~~hematopoietic cells have an adenosine deaminase deficiency and the~~
exogenous gene encodes adenosine deaminase.

15 15. The method of claim 12 wherein the cells are infected with the retrovirus in the presence of an immobilized fibronectin fragment containing an amino acid sequence which provides the cell-binding activity of the CS-1 domain and an amino acid sequence which provides the retrovirus binding activity of the Heparin-II
20 domain.

16. The method of claim 15 wherein the hematopoietic cells comprise human stem cells.

17. The method of claim 16 wherein the hematopoietic cells are characterized as adherent-negative, low density, mononuclear cells.

5 18. An improved method for cellular grafting, comprising the steps of:

obtaining viable hematopoietic cells from an animal donor;

10 infecting the viable hematopoietic cells with a replication-defective recombinant retrovirus vector containing exogenous DNA to produce transduced viable hematopoietic cells, the infecting being in the presence of an immobilized amount of fibronectin and/or a fragment thereof effective to increase the efficiency of cellular

transduction by the retrovirus vector; and

15 introducing the transduced viable hematopoietic cells into an animal recipient as a cellular graft.

19. The method of claim 18 wherein said cellular grafting is for the treatment of a bone marrow blood disorder in the animal recipient.

20

20. The method of claim 18 wherein said cellular grafting is for the treatment of a protein deficiency or abnormality in the animal recipient.

25 21. The method of claim 19 wherein the animal donor and animal recipient are human.

-60-

22. The method of claim 21 wherein the animal recipient is an autologous donor.

5 23. A cellular population suitable for subjection to retroviral-mediated gene transfer, comprising:

viable hematopoietic cells in a culture medium containing immobilized fibronectin, immobilized fibronectin fragments, or an immobilized mixture thereof.

10

24. A culture medium capable of sustaining viable hematopoietic cells and which contains immobilized fibronectin, immobilized fibronectin fragments, or an immobilized mixture thereof.

15

25. A cellular population comprising viable hematopoietic cells transduced by retroviral-mediated gene transfer in the presence of immobilized fibronectin, immobilized fibronectin fragments or an immobilized mixture thereof.

20

26. A method for improving retroviral-mediated gene transfer in viable hematopoietic cells, comprising conducting the retroviral-mediated gene transfer in the presence of immobilized fibronectin, immobilized fibronectin fragments or an immobilized mixture thereof.

25

-61-

27. The method of claim 26 wherein the hematopoietic cells comprise mammalian stem cells.

28. A method for increasing the frequency of transduction of
5 hematopoietic cells by a replication-defective recombinant retrovirus
vector, comprising infecting a population of viable hematopoietic cells
enriched in hematopoietic stem cells with a replication-defective
recombinant retrovirus vector in the presence of an effective
10 immobilized amount of polypeptide containing a first amino acid
sequence which provides the retrovirus-binding activity of the
Heparin-II domain of fibronectin and a second amino acid sequence
which provides the cell-binding activity of the CS-1 domain of
fibronectin, to increase the frequency of transduction of the
hematopoietic cells by the retrovirus vector.

15

29. The method of claim 28 wherein the hematopoietic cells
have a protein deficiency or abnormality and the recombinant
retrovirus vector includes an exogenous gene encoding the protein.

20 30. The method of claim 29 wherein the exogenous gene is a
gene encoding adenosine deaminase.

31. The method of claim 30 wherein the exogenous gene is a
gene encoding human adenosine deaminase.

25

-62-

32. The method of claim 29 wherein the hematopoietic cells are characterized as adherent-negative, low density, mononuclear cells.

5 33. The method of claim 28, wherein said infecting is in the presence of a polypeptide containing both (I) a first amino acid sequence represented by the formula:

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
10 Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr
Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
15 Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp
Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
20 Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro Pro
Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
25 Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

-63-

or a sufficiently similar amino acid sequence thereto to exhibit the ability to bind retroviruses;

and (ii) a second amino acid sequence represented by the formula:

5

Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu His Gly
Pro Glu Ile Leu Asp Val Pro Ser Thr

10

or a sufficiently similar amino acid sequence thereto to exhibit the ability to bind primitive hematopoietic cells.

34. A cellular population comprising viable hematopoietic cells transduced by retroviral-mediated gene transfer in the absence of retroviral producer cells and in the presence of an immobilized amount of a polypeptide containing (i) a first amino acid sequence which provides the retrovirus-binding activity of the Heparin-II domain of fibronectin and (ii) a second amino acid sequence which provides the cell-binding activity of the CS-1 domain of fibronectin, said immobilized amount of polypeptide being effective to increase the frequency of transduction of the hematopoietic cells by the retrovirus vector.

25

35. The cellular population of claim 34 which is enriched in hematopoietic stem cells.

-64-

36. The cellular population of claim 35 wherein said viable hematopoietic cells are human hematopoietic cells enriched in human hematopoietic stem cells.

5 37. The cellular population of claim 36 which is a substantially homogenous population of human hematopoietic cells characterized as adherent-negative, low density, mononuclear cells.

38. The cellular population of claim 36 which has been
10 transduced by a recombinant retrovirus vector containing an exogenous gene to correct a protein deficiency or abnormality in the cells.

39. The cellular population of claim 38 which has been
15 transduced by a recombinant retroviral vector containing a human adenosine deaminase gene in order to correct an adenosine deaminase deficiency in the cells.

20 40. A cellular grafting method, comprising:

introducing into an animal as a cellular graft, viable hematopoietic cells transduced by retroviral-mediated gene transfer in the absence of retroviral producer cells and in presence of an immobilized amount of a polypeptide containing (i) a first amino acid sequence which
25 provides the retrovirus-binding activity of the Heparin-II domain of fibronectin and (ii) a second amino acid sequence which provides the

-65-

cell-binding activity of the CS-1 domain of fibronectin, said immobilized amount of polypeptide being effective to increase the frequency of transduction of the hematopoietic cells by the retrovirus vector.

5

41. The cellular grafting method of claim 40 wherein said viable hematopoietic cells are enriched in hematopoietic stem cells.

42. The cellular grafting method of claim 41 wherein said
10 viable hematopoietic cells are human hematopoietic cells enriched in human hematopoietic stem cells.

43. The cellular grafting method of claim 42 wherein said hematopoietic cells are a substantially homogenous population of
15 human hematopoietic cells characterized as adherent-negative, low density, mononuclear cells.

44. The cellular grafting method of claim 42 wherein said hematopoietic cells have been transduced by a recombinant
20 retrovirus vector containing an exogenous gene to correct a protein deficiency or abnormality in the cells.

45. The cellular grafting method of claim 44 wherein said hematopoietic cells have been transduced by a recombinant
25 retrovirus vector containing a human adenosine deaminase gene in order to correct an adenosine deaminase deficiency in the cells.

-66-

46. A method for obtaining transduced umbilical cord blood cells suitable for a cellular engraftment procedure, comprising:

5 infecting viable hematopoietic cells from umbilical cord blood with a replication-defective recombinant retrovirus vector in the presence of an effective immobilized amount of a polypeptide containing (i) a first amino acid sequence which provides the retrovirus-binding activity of the Heparin-II domain of fibronectin and (ii) a second amino acid sequence which provides the cell-binding activity of the
10 CS-1 domain of fibronectin, said immobilized amount of polypeptide being effective to increase the frequency of transduction of the hematopoietic cells by the recombinant retrovirus vector.

47. The method of claim 46 wherein said hematopoietic cells
15 are human hematopoietic cells from cord blood which have been enriched in hematopoietic stem cells.

48. The method of claim 47 wherein said hematopoietic cells are a substantially homogenous population of human hematopoietic
20 cells from umbilical cord blood characterized as adherent-negative, low density, mononuclear cells.

49. The method of claim 47 wherein the hematopoietic cells have a protein deficiency or abnormality and the recombinant
25 retrovirus vector includes a human gene encoding the protein.

-67-

50. The method of claim 49 wherein the exogenous gene is a gene encoding adenosine deaminase.

51. A cellular population comprising viable hematopoietic cells
5 from umbilical cord blood transduced by retroviral-mediated gene
transfer in the presence of an immobilized amount of a polypeptide
containing (i) a first amino acid sequence which provides the
retrovirus-binding activity of the Heparin-II domain of fibronectin and
(ii) a second amino acid sequence which provides the cell-binding
10 activity of the CS-1 domain of fibronectin, said immobilized amount of
polypeptide being effective to increase the frequency of transduction
~~of the hematopoietic cells from umbilical cord blood by the retrovirus~~
vector.

15 52. The cellular population of claim 51 wherein said
hematopoietic cells are human hematopoietic cells from human
umbilical cord blood.

53. The cellular population of claim 52 which has been
20 enriched in human hematopoietic stem cells from umbilical cord
blood.

54. The cellular population of claim 53 which is a
substantially homogenous population of human hematopoietic cells
25 characterized as adherent-negative, low density, mononuclear cells.

-68-

55. The cellular population of claim 53 which has been transduced by a recombinant retrovirus vector containing an exogenous gene to correct a protein deficiency or abnormality in the cells.

5

56. The cellular population of claim 55 which has been transduced by a recombinant retroviral vector containing a human adenosine deaminase gene in order to correct an adenosine deaminase deficiency in the cells.

10

57. A cellular grafting method, comprising:

~~introducing into an animal as a cellular graft, viable~~
hematopoietic cells from umbilical cord blood transduced by retroviral-mediated gene transfer in the presence of an immobilized
15 amount of a polypeptide containing (i) a first amino acid sequence which provides the retrovirus-binding activity of the Heparin-II domain of fibronectin and (ii) a second amino acid sequence which provides the cell-binding activity of the CS-1 domain of fibronectin, said immobilized amount of polypeptide being effective to increase
20 the frequency of transduction of the umbilical cord stem cells by the retrovirus vector.

58. The cellular grafting method of claim 57 wherein said animal is a human, and said hematopoietic cells are human
25 hematopoietic cells which have been enriched in human hematopoietic stem cells.

-69-

59. The cellular grafting method of claim 58 wherein said hematopoietic cells are a substantially homogenous population of human hematopoietic cells characterized as adherent-negative, low density, mononuclear cells.

60. The cellular grafting method of claim 58 wherein said hematopoietic cells have been transduced by a recombinant retrovirus vector containing an exogenous gene to correct a protein deficiency or abnormality in the cells.

61. The cellular grafting method of claim 60 wherein said hematopoietic cells have been transduced by a recombinant retrovirus vector containing a human adenosine deaminase gene in order to correct an adenosine deaminase deficiency in the cells.

62. A method for increasing the frequency of transduction of hematopoietic cells by a replication-defective recombinant retrovirus vector, comprising infecting hematopoietic cells with a replication-defective recombinant retrovirus vector in the presence of an effective immobilized amount of a recombinant polypeptide containing a first amino acid sequence represented by the formula:

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr

-70-

Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
5 Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp
Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
10 Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro Pro
Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
15 Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

or a sufficiently similar amino acid sequence thereto to exhibit the
ability to bind retroviruses;

20 and a second amino acid sequence represented by the formula:

Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu His Gly
Pro Glu Ile Leu Asp Val Pro Ser Thr

25 or a sufficiently similar amino acid sequence thereto to exhibit the
ability to bind primitive hematopoietic cells.

-71-

63. The method of claim 62 wherein the hematopoietic cells have a protein deficiency or abnormality and the recombinant retrovirus vector includes an exogenous gene encoding the protein.

5

64. The method of claim 63 wherein the exogenous gene is a gene encoding adenosine deaminase.

65. The method of claim 64 wherein the exogenous gene is a
10 gene encoding human adenosine deaminase.

66. The method of claim 63 wherein the hematopoietic cells
comprise human stem cells and said exogenous gene is a human
gene.

15

67. The method of claim 66 wherein the hematopoietic cells are characterized as adherent-negative, low density, mononuclear cells.

20 68. A cellular population comprising viable hematopoietic cells transduced by retroviral-mediated gene transfer in the absence of retroviral producer cells and in the presence of an effective immobilized amount of a recombinant polypeptide which increases the frequency of transduction of the hematopoietic cells, said recombinant
25 polypeptide containing a first amino acid sequence represented by the formula:

-72-

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr
Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
5 Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
10 Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp
Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
15 Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro Pro
Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

20 or a sufficiently similar amino acid sequence thereto to exhibit the
ability to bind retroviruses;

and a second amino acid sequence represented by the formula:

25 Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu His Gly
Pro Glu Ile Leu Asp Val Pro Ser Thr

-73-

or a sufficiently similar amino acid sequence thereto to exhibit the ability to bind primitive hematopoietic cells.

5 69. The cellular population of claim 68 which is enriched in hematopoietic stem cells.

70. The cellular population of claim 69 wherein said viable hematopoietic cells are human hematopoietic cells enriched in
10 human hematopoietic stem cells.

71. The cellular population of claim 70 which is a substantially homogenous population of human hematopoietic cells characterized as adherent-negative, low density, mononuclear cells.

15 72. The cellular population of claim 70 which has been transduced by a recombinant retrovirus vector containing an exogenous gene to correct a protein deficiency or abnormality in the cells.

20 73. The cellular population of claim 72 which has been transduced by a recombinant retroviral vector containing a human adenosine deaminase gene in order to correct an adenosine deaminase deficiency in the cells.

25 74. A cellular grafting method, comprising:

-74-

introducing into an animal as a cellular graft, viable hematopoietic cells transduced by retroviral-mediated gene transfer in the absence of retroviral producer cells and in presence of an effective immobilized amount of a recombinant polypeptide which increases the frequency of transduction of the hematopoietic cells, said recombinant polypeptide containing a first amino acid sequence represented by the formula:

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr
10 Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
15 Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp
Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
20 Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro Pro
Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

25

-75-

or a sufficiently similar amino acid sequence thereto to exhibit the ability to bind retroviruses;

and a second amino acid sequence represented by the formula:

5 .

Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu His Gly
Pro Glu Ile Leu Asp Val Pro Ser Thr

or a sufficiently similar amino acid sequence thereto to exhibit the
10 ability to bind primitive hematopoietic cells.

75. The cellular grafting method of claim 74 wherein said
viable hematopoietic cells are enriched in hematopoietic stem cells.

15 76. The cellular grafting method of claim 75 wherein said
viable hematopoietic cells are human hematopoietic cells enriched in
human hematopoietic stem cells.

20 77. The cellular grafting method of claim 76 wherein said
hematopoietic cells are a substantially homogenous population of
human hematopoietic cells characterized as adherent-negative, low
density, mononuclear cells.

25 78. The cellular grafting method of claim 76 wherein said
hematopoietic cells have been transduced by a recombinant

-76-

retrovirus vector containing an exogenous gene to correct a protein deficiency or abnormality in the cells.

79. The cellular grafting method of claim 78 wherein said
5 hematopoietic cells have been transduced by a recombinant
retrovirus vector containing a human adenosine deaminase gene in
order to correct an adenosine deaminase deficiency in the cells.

80. A method for localizing a retrovirus, comprising:
10 incubating a medium containing a retrovirus in contact with an
effective, immobilized amount of a polypeptide containing an amino
acid sequence which provides the retrovirus-binding activity of the
Heparin-II domain of fibronectin.

15 81. The method of claim 80 wherein said polypeptide
contains an amino acid sequence represented by the formula:

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr
20 Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
25 Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp

-77-

Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
5 Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro Pro
Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

10 or a sufficiently similar amino acid sequence thereto to exhibit the
retrovirus-binding activity of the Heparin-II domain of fibronectin.

82. A method for making a construct useful for enhancing
retroviral-mediated DNA transfer into a predetermined target cell,
15 comprising:

selecting a ligand which binds with specificity to said target cell;
and

covalently coupling said ligand to a polypeptide containing an
amino acid sequence which exhibits the retrovirus-binding activity of
20 the Heparin-II domain of fibronectin.

83. The method of claim 82 wherein said ligand is a cell
adhesive protein, hormone, cytokine, monoclonal antibody,
carbohydrate, metabolite, or a polypeptide from a protein other than
25 fibronectin.

-78-

84. The method of claim 83 wherein said target cell is a malignant cell and said ligand is a hormone.

85. The method of claim 84 wherein said target cell is a breast
5 carcinoma cell and said ligand is a luteinizing hormone releasing hormone, an oestrogen, a progestogen or an anti-progestogen.

86. A method for increasing the frequency of transduction of a population of viable target cells by a retrovirus, comprising
10 infecting the cells with a retrovirus in the presence of an effective immobilized amount of a construct having a ligand which specifically binds to the cells covalently coupled to a polypeptide which binds the retrovirus, said polypeptide containing an amino acid sequence which exhibits the retrovirus-binding activity of the Heparin-II
15 domain of fibronectin.

87. The method of claim 86 wherein said ligand is a cell adhesive protein, hormone, cytokine, monoclonal antibody, carbohydrate, metabolite, or a polypeptide from a protein other than
20 fibronectin.

88. The method of claim 86 wherein said polypeptide is a recombinant polypeptide having an amino acid sequence represented by the formula:

25

-79-

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
 Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr
 Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
 Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
 5 Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
 Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
 Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
 Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
 Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp
 10 Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
 Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
 Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
 Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
 Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro Pro
 15 Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
 Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
 Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

or a sufficiently similar amino acid sequence thereto to exhibit
 20 retrovirus-binding activity.

89. A construct for enhancing retroviral-mediated gene
 transfer into a predetermined target cell, comprising a ligand which
 specifically binds to said target cell covalently coupled to a
 25 polypeptide containing an amino acid sequence which exhibits the
 retrovirus-binding activity of the Heparin-II domain of fibronectin.

-80-

90. The construct of claim 86 wherein said polypeptide is a recombinant polypeptide having an amino acid sequence represented by the formula:

5

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr
Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
10 Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp
15 Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Sev Pro Pro
20 Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

25

or a sufficiently similar amino acid sequence thereto to exhibit
retrovirus-binding activity.

-81-

91. The construct of claim 90 wherein the ligand is a cell adhesive protein, hormone, cytokine, monoclonal antibody, carbohydrate, metabolite, or a polypeptide from a protein other than fibronectin.

5

92. A kit for use in conducting retroviral-mediated DNA transfer into human hematopoietic cells, comprising:

10 (a) substantially pure polypeptide containing (i) a first amino acid sequence of the Heparin-II domain of human fibronectin which exhibits retroviral-binding activity and (ii) a second amino acid sequence which provides the cell-binding activity of the CS-1 domain of human fibronectin;

(b) an artificial substrate upon which to incubate a retroviral vector in contact with human hematopoietic cells; and

15 (c) hematopoietic cell growth factors for prestimulating the hematopoietic cells.

93. The kit of claim 90 wherein said substantially pure polypeptide is immobilized on said artificial substrate.

20

94. The kit of claim 90 which also includes:

(d) a recombinant retroviral vector for transducing the human hematopoietic cells.

-82-

95. The kit of claim 90 wherein said substantially pure polypeptide (a) comprises a recombinant polypeptide having an amino acid sequence represented by the formula:

Ala Ile Pro Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr
5 Ser Leu Ser Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr
Arg Val Arg Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile
Asn Leu Ala Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val
Ala Thr Lys Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr
Ser Arg Pro Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro
10 Pro Arg Arg Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile
Ser Trp Arg Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala
Val Pro Ala Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Sys Pro Asp
Val Arg Ser Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys
Ile Tyr Leu Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val
15 Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu
Ala Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala
Arg Ile Thr Gly Tyr Ile Ile Lys Tyr Glu Sys Pro Gly Ser Pro Pro
Arg Glu Val Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile
Thr Gly Leu Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu
20 Lys Asn Asn Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr

or a sufficiently similar amino acid sequence thereto to exhibit retrovirus-binding activity.

25 96. The kit of claim 95 wherein said substantially pure recombinant polypeptide is immobilized on said artificial substrate.

-83-

97. The kit of claim 96 which also includes:

- (d) a recombinant retroviral vector for transducing the human hematopoietic cells.

5

98. A method for preparing a viable primitive hematopoietic cellular population, comprising contacting a cellular population containing viable primitive hematopoietic cells with an effective immobilized amount of a polypeptide which exhibits the cell-binding activity of the CS-1 domain of fibronectin, to bind primitive hematopoietic cells to said immobilized amount of polypeptide.

10

99. The method of claim 98, wherein said polypeptide has an amino acid sequence represented by the formula:

15

Asp Glu Leu Pro Gln Leu Val Thr Leu Pro His Pro Asn Leu His Gly
Pro Glu Ile Leu Asp Val Pro Ser Thr

or a sufficiently similar amino acid sequence thereto to exhibit the ability to bind primitive hematopoietic cells.

20




FIG. 1

2/11




FIG. 2




FIG. 3

4/11




FIG. 4

5/11




FIG. 5

6/11




FIG. 6




FIG. 7

8/11




FIG. 8

9/11




FIG. 9

10/11




FIG. 10

11/11




FIG. 11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03817

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 424/93.1, 93.2; 435/69.1, 172.1, 172.3, 240.2, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1, 93.2; 435/69.1, 172.1, 172.3, 240.2, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog, Biosis, Medline, Biotech

Search Terms: retroviral vector, fibronectin, transduction, CS-1, adenosine deaminase

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	The Journal of Cell Biology, Volume 102, issued February 1986, Patel et al., "The Fibronectin Receptor on Mammalian Erythroid Precursor Cells: Characterization and Developmental Regulation", pages 449-456, see pages 451-452.	1-99
A	The Journal of Biological Chemistry, Volume 256, Number 14, issued 25 July 1981, Ruoslahti et al., "Alignment of Biologically Active Domains in the Fibronectin Molecule", pages 7277-7281, see page 7280.	1-17

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed	G	document member of the same patent family

Date of the actual completion of the international search

07 MAY 1995

Date of mailing of the international search report

26 MAY 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID GUZO

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

International application No.
PCT/US95/03817

International application No.
PCT/US95/03817

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Journal of Experimental Medicine, Volume 178, issued August 1993, Moritz et al., "Human Cord Blood Cells as Targets for Gene Transfer: Potential Use in Genetic Therapies of Severe Combined Immunodeficiency Disease", pages 529-536, see page 534.	46-56
A	Proceedings of the National Academy of Sciences, Volume 86, issued November 1989, Lim et al., "Long-term Expression of Human Adenosine Deaminase in Mice Transplanted with Retrovirus-infected Hematopoietic Stem Cells", pages 8892-8896, see page 8894.	3, 4, 13, 14, 30, 31, 39, 45, 50, 56, 61, 64, 65, 73, 79
A	Virology, Volume 167, issued 1988, Markowitz et al., "Construction of a Safe and Effective Amphotropic Packaging Cell Line", pages 400-406, see Tables 1 and 2.	1-99

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03817

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 38/00, 38/16, 38/39, 48/00, 49/00; C12N 15/00, 15/10, 15/48, 15/86

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.